In summary, targeting of CD44 by siRNAs or antibodies for therapy and the use of HA-coated nanoparticles or of anti-CD44 antibody conjugates for the delivery of therapeutic agents have been examined as attractive strategies in the treatment of cancer and chronic diseases. The gene discussed is CD44; the disease is cancer.